FGFR-4-targeted CARs for rhabdomyosarcoma

Rimas J. Orentas, PhD, Seattle Children's Research Institute, Seattle, WA, outlines the development of FGFR4-targeted chimeric antigen receptor (CAR) T-cells for the treatment of rhabdomyosarcoma. FGFR4 is upregulated in rhabdomyosarcoma tumors compared to normal tissue, making it a suitable candidate for CAR-T therapy. Two novel CAR-T therapies targeting FGFR4 which demonstrated high cellular toxicity and tumor specificity in vitro are being further developed and will be tested for in vivo efficacy against metastatic and intramuscular rhabdomyosarcoma. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.